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Summary
While antigens from Schistosoma schistosomula have been suggested as potential 
vaccine candidates, the association between antibody responses with schistosomula 
antigens	 and	 infection	 intensity	 at	 reinfection	 is	 not	 well	 known.	 Schistosoma 
mansoni-	infected	individuals	were	recruited	from	a	schistosomiasis	endemic	area	in	
Uganda	(n	=	372),	treated	with	40	mg/kg	praziquantel	(PZQ)	and	followed	up	at	five	
weeks	and	at	one	year	post-	treatment.	Pre-	treatment	and	five	weeks	post-	treatment	
immunoglobulin	(Ig)	E,	IgG1	and	IgG4	levels	against	recombinant	schistosomula	an-
tigens	 rSmKK7,	 rSmLy6A,	 rSmLy6B	 and	 rSmTSP7	 were	 measured	 using	 ELISA.	
Factors	 associated	with	 detectable	 pre-	treatment	 or	 post-	treatment	 antibody	 re-
sponse	against	the	schistosomula	antigens	and	the	association	between	five-	week	
antibody	responses	and	one	year	post-	treatment	reinfection	intensity	among	anti-
body	 responders	 were	 examined.	 Being	 male	 was	 associated	 with	 higher	 pre-	
treatment	IgG1	to	rSmKK7,	rSmLy6a	and	AWA.	Five	weeks	post-	treatment	antibody	
responses	against	schistosomula	antigens	were	not	associated	with	one	year	post-	
treatment	reinfection	intensity	among	antibody	responders’	antibody	levels	against	
rSmKK7,	rSmLy6B	and	rSmTSP7	dropped,	but	increased	against	rSmLy6A,	AWA	and	
SEA	at	five	weeks	post-	treatment	among	antibody	responders.	S. mansoni-	infected	
individuals	exhibit	detectable	antibody	responses	to	schistosomula	antigens	that	are	
affected	by	treatment.	These	findings	indicate	that	schistosomula	antigens	induce	
2 of 11  |     EGESA Et Al.
1  | INTRODUC TION
Approximately	 206	 million	 people	 worldwide	 required	 treatment	
for schistosomiasis in 2016.1	Control	programmes	in	affected	coun-
tries have reduced the morbidity associated with schistosomiasis,2 
yet despite this, treatment is unable to prevent reinfection with 
Schistosoma	species,	and	consequently,	transmission	of	schistosomi-
asis	remains	a	global	problem.	Mass	drug	administration	with	prazi-
quantel	 (PZQ)	 alone	 may	 not	 ultimately	 control	 schistosomiasis,3 
and therefore, a solution such as a prophylactic vaccine is needed to 
provide	 long-	term	 immunity	and	preferably	complement	 the	PZQ-	
based schistosomiasis control strategy.4	There	 is	currently	no	vac-
cine against schistosomes, and only a few vaccine candidates are in 
clinical trials. Despite the limited success, defined antigens continue 
to	be	investigated	as	vaccine	targets.	Among	these	are	those	from	
the	larvae	of	the	schistosome,	known	as	schistosomula.	The	schisto-
somula	develop	when	free-	living	cercariae	penetrate	host	skin,	lose	
their	bifurcated	tails	and	shed	their	cercarial	glycocalyx	coat	in	the	
skin	in	a	process	called	transformation.	Early	work	on	schistosome	
parasite	biology	showed	that	transformation	makes	the	skin	schisto-
somula	vulnerable	to	killing	by	host	immune	responses.5	This	killing	
is	mediated	through	complement	fixation	6,7	and	antibody	(IgE,	IgA	
and	IgG)-	dependent	cell-	mediated	cytotoxicity	(ADCC).8-10	The	anti-
bodies	coat	the	schistosomula	and	allow	eosinophils	to	kill	the	para-
site in vitro.11,12	This	suggests	that	the	schistosomula	are	a	potential	
source of vaccine candidates.
By	 examining	 the	 S. mansoni transcriptome, genes that are 
highly	 expressed	 or	 upregulated	 during	 the	 schistosomula	 stage	
compared to the infective cercariae can be identified.13 Indeed, 
DNA	 microarray-	based	 analysis	 of	 the	 S. mansoni life cycle has 
revealed	 schistosomula-	enriched	 gene	 products,	 such	 as	 those	
coding	 for	 SmKK7	 (smp_194830),	 S. mansoni lymphocyte antigen 
6	isoforms	A	and	B	(SmLy6A;	smp_019350,	SmLy6B;	smp_105220)	
and S. mansoni	tetraspanin	7	(SmTSP7;	smp_099770).14	SmLy6A	and	
SmLy6B	 are	 probably	 glycophosphatidylinositol	 (GPI)-	anchored	
antigens, found in schistosomula,13,15 but also in adult tegumental 
and mesenchymal tissues.16,17	Although	SmLy6A	and	SmLy6B	are	
homologues	of	human	CD59,	which	 inhibits	 the	 formation	of	 the	
complement	membrane	attack	complex,	 they	do	not	 inhibit	com-
plement	fixation	and	their	function	remains	unknown.17	SmKK7	is	
a putative immunomodulatory protein found in the peripheral ner-
vous system of S. mansoni adults 18	and	upregulated	in	7-	and	14-	
day schistosomula.15	SmTSP7	is	a	membrane-	spanning	tetraspanin	
with	unknown	function	but	has	been	identified	in	the	tegument	of	
the adult worm.19
Epidemiological	studies	have	shown	that	specific	host	antibodies	
to Schistosoma	antigens	contribute	to	immunity	to	schistosomiasis.	For	
instance, antibody responses targeting S. mansoni adult worm antigens 
are associated with resistance or susceptibility to reinfection of people 
at	risk	in	endemic	areas.20,21	Although	adult	worm	antigen-	specific	IgE	
is associated with resistance against reinfection, it is important to note 
that	vaccine	candidates	that	 induce	 IgE	production	may	not	be	safe	
for	use,	particularly	 in	previously	helminth-	infected	 individuals.	This	
was	accentuated	during	a	trial	 involving	a	hookworm	vaccine	candi-
date	that	was	discontinued	when	previously	hookworm-	infected	par-
ticipants	developed	an	IgE-	mediated	allergic	reaction.22,23	The	same	
hookworm	vaccine	had	earlier	 been	 shown	 to	be	 safe	with	healthy	
hookworm-	naive	individuals.24	This	suggests	that	helminth	(including	
Schistosoma)	antigens	should	be	pre-	clinically	screened	using	sera	from	
infected	people	to	determine	whether	antigen-	specific	IgE	is	present.
On	the	other	hand,	IgG4	blocks	IgE-	mediated	protective	immu-
nity	by	competing	with	IgE	to	bind	shared	epitopes	25 and engaging 
the	 inhibitory	 IgG	 receptor,	 FcγIIb, that downregulates signalling 
from	the	IgE	receptor,	FcεRI, on effector cells.26,27	As	a	result,	acti-
vation of effector cells is inhibited 28 and protective responses may 
be less effective. Indeed, Schistosoma-	infected	 people,	 especially	
children	(who	are	the	most	susceptible	to	reinfection),	produce	high	
levels	 of	 IgG4.29,30	 Although	 antibody	 responses	 (IgE	 and	 IgG)	 to	
crude	purified	extracts	of	schistosomula	have	been	shown	to	con-
tribute to human resistance,31,32	 few	 studies	 have	 looked	 at	 anti-
body responses to recombinant schistosomula antigens.33
The	aim	of	this	study	was	to	determine	how	infection	intensity,	
age	and	sex	affect	antibody	responses	to	the	recombinant	S. mansoni 
schistosomula	antigens	 rSmLy6A,	 rSmLy6B,	 rSmKK7	and	rSmTSP7	
in an endemic population. We also analysed the effect of treatment 
on the antibody responses against these recombinant antigens and 
the	correlation	between	the	antibody	and	cytokine	responses	(in	the	
companion	paper).	Finally,	we	examined	whether	pre-	or	five	weeks	
post-	treatment	antibody	responses	were	associated	with	reinfection	
one year later.
2  | MATERIAL S AND METHODS
2.1 | Ethical statement
Informed	consent	was	obtained	from	adults	in	Namoni	to	participate	
in	this	study.	Children	gave	written	assent	to	participate	in	the	study.	
The	 Makerere	 University	 School	 of	 Biomedical	 Sciences	 Higher	
Degrees	 Research	 and	 Ethics	 Committee	 (reference	 number	 SBS	
highly varied antibody responses and could have implications for vaccine 
development.
K E Y W O R D S
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300)	and	the	Uganda	National	Council	for	Science	and	Technology	
(reference	number	HS	1040)	approved	this	work.
2.2 | Recruitment of study participants
Individuals	were	 recruited	 from	Namoni	village,	a	Ugandan	 fishing	
community	that	is	endemic	with	schistosomiasis	at	the	shore	of	Lake	
Victoria	as	part	of	TheSchistoVac	study	(http://www.theschistovac.
eu)	to	develop	antigens	for	a	prophylactic	schistosomiasis	vaccine.	A	
total of 372 individuals aged between 6 and 40 years were recruited 
from	Namoni	(Figure	1).	TheSchistoVac	cohort	in	Namoni	has	been	
described elsewhere.34	 In	 September	 2011,	 the	 participants	were	
treated	with	two	doses	of	praziquantel	(40	mg/kg)	one	week	apart	
and	followed	up	for	5	weeks	and	a	year.	Infection	intensity	was	de-
termined	 from	 stool	 samples	 collected	 pre-	treatment,	 at	 5	weeks	
for	 efficacy	 of	 the	 PZQ	 treatment	 and	 one	 year	 for	 reinfection.	
Participants	 were	 asked	 to	 donate	 a	 venous	 blood	 sample	 imme-
diately	before	the	first	praziquantel	treatment	and	a	further	blood	
sample	five	weeks	later.	Plasma	samples	were	separated,	stored	and	
later tested for antibody responses.
Of those recruited and followed up to the end of the study, 244 
(65.6%)	 completed	 the	 study.	 However,	 240	 (64.5%)	 of	 those	 re-
cruited	had	complete	data	on	infection	intensity,	age,	sex	and	levels	
of	IgG1,	IgG4	and	IgE	to	AWA,	SEA	and	the	antigens	at	baseline,	five	
weeks	and	one	year	after	PZQ	treatment	(Figure	1).
The	water	contact	behaviour	of	the	study	participants	was	ob-
tained and recorded before treatment and included the duration 
of	contact	 (time	spent	 in	 the	 lake)	and	whether	or	not	 the	partici-
pants bathed, swam, played, fished or processed fish, washed uten-
sils	or	 clothes	 in	 the	 lake,	or	 engaged	 in	 transport	 across	 the	 lake	
or	 engaged	 in	 farm	 irrigation	 using	 lake	water.	 The	water	 contact	
behaviour	was	self-	reported	during	questionnaire	interviews.
2.3 | Stool examination by microscopy
Before	treatment,	three	stool	samples	were	collected	on	three	con-
secutive	days	in	the	morning	and	two	thick	smears	made	from	each	
sample.	The	six	slides	were	examined	using	the	Kato	Katz	method	
for the number of S. mansoni eggs as previously described.35	 The	
egg	count	was	the	average	of	the	six	slides	from	the	three	samples.	
The	 infection	 intensity	 was	 calculated	 by	multiplying	 the	 average	
egg	 count	with	24	and	expressed	as	egg	 count	per	 gram	of	 stool.	
The	 infection	 intensity	 of	 the	 participants	was	 classified	 as	 either	
light	(1-	99	epg),	moderate	(100-	399	epg)	or	heavy	(>400	epg)	based	
on	the	WHO	criteria.36	Additional	stool	samples	were	collected	five	
weeks	and	one	year	after	PZQ	treatment.	Of	 the	240	 infected	 in-
dividuals,	186	(77.5%)	had	no	eggs	(putatively	cured)37	by	the	Kato	
Katz	 method	 performed	 on	 three	 stool	 samples	 five	 weeks	 after	
PZQ	treatment.	One	year	after	PZQ	treatment,	154	(82.8%)	of	those	
cured	were	egg	positive,	determined	by	the	Kato	Katz	method	per-
formed	on	six	smears	from	three	stool	samples.	Reinfection	was	de-
fined	as	the	presence	of	eggs	at	one	year	after	PZQ	treatment.38
2.4 | Schistosoma mansoni antigens
The	antigens	used	in	this	study	were	S. mansoni	adult	worm	(AWA)	
and	 egg	 antigens	 (SEA)	 and	 recombinant	 schistosomula	 antigens	
rSmKK7,	 rSmLy6A,	 rSmLy6B	 and	 rSmTSP7.	 These	 antigens	 were	
identified	 as	 highly	 expressed	 products	 in	 the	 schistosomula	 life	
cycle stage after screening the Schistosoma transcriptome using 
DNA	microarrays,	as	previously	described.14,16	Specifically,	a	>5-	fold	
increase	in	expression	when	comparing	normalized	expression	aver-
ages	from	snail	(egg,	miracidia,	mother	sporocyst	and	daughter	spo-
rocyst)	to	schistosomula	(3-	h,	24-	h,	3-	day	and	6-	day	schistosomula)	
life stages was observed.16	Recombinant	antigens	were	expressed	in	
Escherichia coli and purified using methods as previously described 
for	rSmKK7	(smp_194830),14	rSmLy6A	and	rSmLy6B.15	For	SmTSP7,	
78	amino	acids	representing	the	extracellular	loop	2	of	the	protein	
(108-	185AA;	 defined	 by	 TMHMM2.0	 software	 39	were	 expressed	
using	 the	 same	 vector,	 expression	 parameters	 and	 purification	
methods	as	SmLy6A	and	SmLy6B.	The	selected	proteins	used	in	this	
study	were	screened	for	in	silico	similarity	to	known	allergens,	and	
any	with	a	similarity	were	discarded	from	the	pipeline.	The	selected	
proteins	were	further	screened	for	IgE	reactivity	using	sera	from	a	
schistosomiasis endemic cohort, Musoli. It was found that Musoli 
residents	had	minimal	IgE	reactivity	to	these	proteins,	and	the	anti-
gens were therefore selected for further study.
2.5 | Blood collection and estimation of 
antibody responses
Plasma samples were separated from whole blood before and five 
weeks	after	PZQ	treatment	by	centrifugation	and	stored	at	-	20°C	
F IGURE  1 The	study	profile	describing	the	screening,	
recruitment	and	follow-	up	of	the	study	participants
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until	ready	for	use.	The	concentrations	of	IgG1,	IgG4	and	IgE	spe-
cific	 for	 the	 schistosomula	 antigens	 (rSmKK7,	 rSLy6A,	 rSmLy6B,	
rSmTSP7)	 and	 the	 crude	 parasite	 antigens	 (AWA	and	 SEA)	were	
quantified	using	ELISA	as	previously	described.40	Briefly,	the	well	
surfaces	 of	 384-	well	Microlon	 600	 high-	binding	 plates	 (Greiner,	
Meadville,	PA,	USA)	were	washed	with	distilled	water	and	coated	
overnight	at	4°C	with	15	μL/well	of	antigen	diluted	in	sodium	bi-
carbonate	 solution.	 The	 saturating	 concentrations	 of	 rSmKK7,	
rSmLy6A,	 rSmLy6B,	 rSmTSP7,	 AWA	 and	 SEA	 used	 were	 13.40,	
6.25, 9.60, 6.25, 8 and 1.25 μg/mL,	respectively.	The	plates	were	
blocked	 for	1	h,	 and	 sera	 from	 the	 infected	Ugandan	 individuals	
and	 uninfected	 nonendemic	 European	 control	 samples	 were	 di-
luted	1/200	for	IgG1	and	IgG4	and	1/20	dilution	for	IgE,	plated	and	
incubated	overnight	at	4°C.	The	serum	samples	were	tested	in	du-
plicate.	Diluted	monoclonal	mouse	anti-	human	IgG1,	IgG4	and	IgE	
biotin	(Pharmingen,	San	Diego,	CA,	USA)	were	used	and	incubated	
at	room	temperature	for	2	h	for	IgG1	and	IgG4	or	+4°C	overnight	
for	 IgE,	 respectively.	 Detection	 was	 performed	 using	 Poly-	HRP	
streptavidin	complex	 (Mast	Group,	UK)	and	OPD	substrate	solu-
tion	 (Sigma,	 Ronkonkoma,	 NY,	 USA).	 The	 reaction	 was	 stopped	
using 2M sulphuric acid and absorbance read at test wavelength 
490	nm	 and	 reference	wavelength	630	nm	on	 a	PowerWave	HT	
microplate	 reader	 (BioTek	 Instruments	 Inc.,	Winooski,	 VT,	USA).	
Gen	5	software	(BioTek	Instruments	Inc.)	generated	antibody	re-
sponses from the standard curve.
2.6 | Cytokine responses to schistosomula antigens
Stored	 peripheral	 blood	mononuclear	 cells	 were	 thawed,	 stimu-
lated	with	rSmKK7,	rSLy6A,	rSmLy6B	and	rSmTSP7	and	the	super-
natant	collected	after	24	h	and	tested	for	cytokines,	chemokines	
and	growth	 factors	 as	 described	 in	 the	 companion	paper	 (Egesa	
unpublished).
2.7 | Statistical methods
Antibody	(IgG1,	IgG4	and	IgE)	levels	against	the	schistosomula	anti-
gens	before	treatment	were	categorized	as	antibody	responders	and	
nonresponders.	 Antibody	 responders	 were	 participants	 with	 anti-
body levels greater than the mean plus 3 standard deviations against 
the schistosomula antigens detected in the plasma of 26 nonen-
demic	European	individuals.	Factors	associated	with	detectable	pre-	
treatment	or	post-	treatment	antibody	(IgG1,	IgG4	and	IgE)	responses	
against crude schistosome and schistosomula antigens were deter-
mined	using	multiple	logistic	regression.	The	correlation	between	the	
antibody	 levels	 and	 cytokine	 responses	 to	 schistosomula	 antigens	
among	antibody	responders	was	investigated	using	Spearman’s	rank	
correlation. Multivariable logistic regression was used to investigate 
whether	 detectable	 five	weeks	 post-	treatment	 antibody	 responses	
were	associated	with	one	year	post-	treatment	 reinfection	 intensity.	
Because	 antibody	 levels	 were	 not	 normally	 distributed,	 the	 levels	
were	log-	transformed	and	the	transformed	antibody	levels	compared	
before	 and	 5	weeks	 after	 treatment	 among	 responders,	 using	 the	
paired t-	test.	 Statistical	 analysis	was	performed	using	Stata	version	
13	 (Stata	 Corp,	 College	 Station,	 TX,	 USA)	 and	 graphs	 drawn	 using	
GraphPad	Prism	version	6.0	g	(GraphPad	Software,	Inc.,	,	San	Diego,	
CA,	USA).
3  | RESULTS
3.1 | Demographics of the study participants
Table	1	 shows	 the	 demographics	 of	 the	 Namoni	 study	 partici-
pants	 at	 baseline.	 The	 age	 range	 of	 the	 study	 participants	 was	
6-	40	years.	 There	 were	 slightly	 more	 females	 than	 males.	 The	
study	 participants	mainly	 had	 a	 heavy	 infection	 intensity	 (>400	
epg)	before	treatment.
The	majority	of	the	study	participants	spent	no	longer	than	one	
hour	a	day	 in	 the	 lake	 (Table	S1).	However,	 the	male	 study	partic-
ipants	 spent	more	 time	 in	 the	 lake	 than	 their	 female	counterparts	
(X2	(5,	N	=	226)	=	20.24,	P	=	0.001).	There	was	no	age	difference	in	
water	contact	behaviour	(X2	(10,	N	=	226)	=	16.37,	P	=	0.089).
3.2 | Number of antibody responders to the 
schistosomula antigens
The	 number	 and	 percentage	 of	 responders	 are	 shown	 in	 Table	2.	
There	was	 a	 substantial	 number	 of	 IgG1	 responders	 to	 the	 schis-
tosomula	antigens	rSmKK7	(63.3%),	rSmLy6b	(76.3%)	and	rSmTSP7	
(43.8).	Generally,	the	prevalence	of	IgG4	responders	to	the	schisto-
somula	antigens	was	below	22%.	IgE	responders	to	rSmKK7	(26.3%)	
and	SmLy6b	(43.3%)	were	observed	among	the	study	participants.	
The	number	of	IgG1,	IgG4	and	IgE	responders	to	the	crude	S. man-
soni	AWA	and	SEA	was	relatively	high	compared	to	the	schistoso-
mula antigens.
3.3 | Age and sex were associated with pre- 
treatment and post- treatment antibody responses 
against the crude antigens among antibody responders
Tables	3	and	S2	show	factors	associated	with	pre-	treatment	and	five	
weeks	post-	treatment	antibody	responses	against	crude	S. mansoni 
antigens, respectively.
TABLE  1 Baseline	demographics	of	the	study	participants	
(N	=	240)
Factor Level n (%)
Sex Female 135	(56)
Age	(years) 6-	9 74	(31)
10-	13 76	(32)
>14 90	(37)
Pre-	treatment	infection	
intensity	(epg)
Light	(1-	99) 44	(18)
Moderate	(100-	399) 41	(17)
Heavy	(>400) 155	(65)
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Before	treatment,	being	male	was	associated	with	higher	pre-	
treatment	IgG1	to	AWA	(P	=	0.013)	and	IgE	to	AWA	(P	=	0.005)	and	
SEA	(P	=	0.029)	after	adjusting	for	gender.	Being	10	years	and	over	
was	associated	with	higher	IgE	levels	against	AWA	(P	=	0.031).
Table	S2	shows	factors	 that	were	associated	with	five	weeks	
post-	treatment	 antibody	 responses	 against	 the	 crude	 S. mansoni 
antigens,	respectively.	Five	weeks	following	treatment,	being	male	
was	associated	with	higher	IgE	to	AWA	(P	=	0.015)	after	adjusting	
for	age.	Being	10	years	and	over	was	associated	with	higher	five	
weeks	post-	treatment	 IgE	 levels	against	AWA	after	adjusting	 for	
gender	(P	=	0.025).
3.4 | Being male was associated with pre- 
treatment and post- treatment antibody responses 
against the recombinant schistosomula antigens 
among antibody responders
Tables	4	 and	 S3	 show	 factors	 that	 were	 associated	 with	 pre-	
treatment	 and	 five	 weeks	 post-	treatment	 antibody	 responses	
against the recombinant schistosomula antigens among respond-
ers,	 respectively.	 Before	 treatment,	 being	 male	 was	 associated	
with	higher	IgG1	to	rSmKK7	(P	=	0.009)	and	rSmLy6a	(P	=	0.006).	
Five	weeks	 following	 treatment,	being	male	was	associated	with	
higher	 IgG4	 levels	 against	 SmKK7	 (P	=	0.0001)	 and	 SmLy6B	
(P	=	0.045).
3.5 | Those reinfected after treatment had high pre- 
treatment intensity
Predisposition describes the phenomenon where those that are re-
infected after treatment tend to be the same individuals who had 
high	pre-	treatment	intensity.	The	pre-	and	one	year	post-	treatment	
infection intensity in these individuals was positively correlated 
(r2 =	0.418,	P	<	0.0001)	(Figure	2).	Having	a	moderate	pre-	treatment	
intensity decreases the log odds of being resistant to reinfection 
by	 1.4	 (P	=	0.014),	 compared	 to	 having	 a	 light	 infection	 intensity	
(Data	not	shown).	In	addition,	having	a	heavy	pre-	treatment	inten-
sity decreased the log odds of being resistant to reinfection by 1.3 
(P	=	0.010),	compared	to	those	with	a	light	infection	intensity.	Those	
resistant to reinfection were defined as having no eggs one year 
after	treatment.	Overall,	the	effect	of	pre-	treatment	intensity	on	re-
infection	intensity	(and	subsequently	resistance	to	reinfection)	was	
statistically	significant	after	adjusting	for	age	and	gender	(P	=	0.011).
3.6 | Five weeks post- treatment antibody responses 
against schistosomula antigens were not associated 
with one year post- treatment reinfection intensity 
among antibody responders
To	 assess	 whether	 antibody	 responses	 to	 schistosomula	 antigens	
predicted reinfection, the association between detectable five 
Antibody
Antibody responders, n (%)a
SmKK7 SmLy6a SmLy6b SmTSP7 AWA SEA
IgG1 152	(63.3) 32	(13.33) 182	(76.3) 105	(43.8) 220	(91.7) 223	(92.9)
IgG4 51	(21.3) 9	(3.8) 28	(11.7) 15	(6.3) 219	(91.3) 233	(97.1)
IgE 63	(26.3) 9	(3.8) 104	(43.3) 13	(5.4) 123	(51.3) 75	(31.3)
aAs	a	percentage	of	the	240	individuals	whose	data	were	analysed.	
TABLE  2 Antibody	responders	to	the	
schistosomula antigens
TABLE  3 Factors	associated	with	pre-	treatment	IgG1,	IgG4	and	IgE	detectable	response	against	crude	Schistosoma mansoni antigens
Antigen Factor Level
IgG1 IgG4 IgE
Adjusteda OR (95% 
CI) P- value
Adjusteda OR 
(95% CI) P- value
Adjusteda OR (95% 
CI) P- value
AWA Sex Female 1 0.013 1 0.125 1 0.005
Male 5.00	(1.40-	17.86) 2.20	(0.80-	5.99) 2.15	(1.25-	3.68)
Age	
(years)
6 to 9 1 0.089 1 0.203 1 0.031
10 to 13 4.09	(0.78-	21.37) 3.32	(0.84-	13.24) 2.19	(1.12-	4.29)
14+ 0.73	(0.25-	2.10) 0.54	(0.15-	2.01) 2.17	(1.13-	4.14)
SEA Sex Female 1 0.290 1 0.368 1 0.029
Male 1.81	(0.60-	5.48) 2.17	(0.40-	11.73) 1.87	(1.07-	3.26)
Age	
(years)
6 to 9 1 0.037 1 0.560 1 0.854
10 to 13 4.67	(0.51-	43.19) 3.54	(0.35-	35.33) 0.82	(0.41-	1.65)
14+ 0.41	(0.13-	1.35) 1.41	(0.26-	7.37) 0.88	(0.45-	3.00)
OR, odds ratio.
aAdjusted	for	either	sex	or	age.	
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weeks	 post-	treatment	 antibody	 responses	 against	 schistosomula	
antigens	and	one	year	post-	treatment	reinfection	 intensity	was	 in-
vestigated.	 There	was	 no	 consistent	 association	 between	 the	 de-
tectable	 five	 weeks	 post-	treatment	 antibody	 responses	 against	
schistosomula	antigens	and	reinfection	intensity	one	year	after	PZQ	
treatment	(Table	5).
3.7 | PZQ treatment differentially affects antibody 
responses against the recombinant schistosomula 
antigens among antibody responders
The	antibody	levels	against	the	recombinant	schistosomula	antigens	
pre-	and	post-	treatment	among	antibody	responders	are	shown	 in	
Figure	3.	 Among	 the	 recombinant	 antigens,	 IgG1	 to	 rSmLy6A	 in-
creased	five	weeks	post-	treatment	(P	<	0.0001).	On	the	other	hand,	
levels	 of	 IgG1	 to	 rSmKK7	 (P	<	0.0001),	 rSmLy6B	 (P	<	0.0001)	 and	
rSmTSP7	(P	=	0.0006)	and	IgE	to	rSmKK7	(P	<	0.0001)	and	rSmLy6B	
(P	<	0.0001)	dropped	five	weeks	following	treatment.	IgG4	levels	to	
the schistosomula antigens were not affected by the treatment, with 
the	exception	of	IgG4	to	rSmTSP7	(P	=	0.0025).	The	lack	of	an	IgG4	
response	is	likely	due	to	the	fact	that	there	were	very	few	IgG4	re-
sponders to the recombinant schistosomula antigens.
The	effect	of	PZQ	treatment	on	crude	antigens	AWA	and	SEA	
among	antibody	responders	is	shown	in	Figure	S1.	IgG1	to	the	crude	
antigens	 AWA	 (P	<	0.0001)	 and	 SEA	 (P	<	0.0001),	 IgG4	 to	 AWA	
(P	<	0.0001)	and	IgE	to	AWA	(P	=	0.003)	increased	five	weeks	post-	
treatment.	 IgG4	 (P	=	0.526)	and	 IgE	 (P	=	0.438)	 levels	 to	SEA	were	
not affected by treatment.
4  | DISCUSSION
Schistosomula	 are	 vulnerable	 to	 both	 complement	 and	 antibody-	
dependent	cell-	mediated	cytotoxicity	in	in	vitro	experiments.9-11,41,42 
This	 makes	 the	 newly	 transformed	 schistosomulum	 a	 plausible	
source of candidate antigens for a vaccine against S. mansoni.43 
There	 is	 information	on	antibody	responses	to	various	Schistosoma 
antigens, but protective antibody responses against schistosomula 
have not been identified yet and factors that affect these antibody 
responses	are	unknown.	In	this	study,	we	have	presented	an	analy-
sis	 of	 antibody	 responses	 to	 schistosomula-	enriched	 antigens	 in	 a	
cohort	from	an	endemic	area.	Not	surprisingly,	we	found	that	being	
male	was	associated	with	high	pre-	and	five	weeks	post-	treatment	
antibody	responses	against	the	schistosomula	antigens	SmKK7	and	
TABLE  4 Factors	associated	with	pre-	treatment	IgG1,	IgG4	and	IgE	detectable	responses	against	Schistosoma mansoni schistosomula 
antigens
Antigen Factor Level
IgG1 IgG4 IgE
Adjusteda OR 
(95% CI) P- value
Adjusteda OR (95% 
CI) P- value
Adjusteda OR (95% 
CI) P- value
SmKK7 Sex Female 1 0.009 1 0.143 1 0.625
Male 2.09	(1.20-	3.65) 1.62	(0.85-	3.07) 0.86	(0.48-	1.56)
Age	
(years)
6 to 9 1 0.739 1 0.019 1 0.943
10 to 13 1.31	(0.66-	2.60) 1.96	(0.92-	4.18) 0.88	(0.42-	1.84)
14+ 1.15	(0.60-	2.21) 0.66	(0.28-	1.53) 0.96	(0.60-	2.21)
SmLy6a Sex Female 1 0.006 1 0.073 1 0.549
Male 3.13	(1.39-	7.02) 4.37	(0.87-	21.89) 1.5	(0.39-	5.91)
Age	
(years)
6 to 9 1 0.441 1 0.380 1 0.716
10 to 13 0.93	(0.37-	2.28) 1.18	(0.27-	5.04) 0.51	(0.09-	2.85)
14+ 1.15	(0.21-	1.45) 0.25	(0.03-	2.31) 0.65	(0.13-	3.08)
SmLy6b Sex Female 1 0.304 1 0.713 1 0.438
Male 1.39	(0.74-	2.59) 1.17	(0.51-	2.67) 0.81	(0.48-	1.38)
Age	
(years)
6 to 9 1 0.069 1 0.001 1 0.082
10 to 13 2.47	(1.08-	5.61) 3.60	(1.33-	9.76) 1.98	(1.02-	3.83)
14+ 1.10	(0.54-	2.20) 0.54	(0.15-	2.01) 1.12	(0.59-	2.12)
SmTSP7 Sex Female 1 0.798 1 0.117 1 0.186
Male 1.07	(0.63-	1.81) 2.46	(0.79-	7.56) 2.19	(0.68-	7.00)
Age	
(years)
6 to 9 1 0.309 1 0.224 1 0.969
10 to 13 1.58	(0.82-	3.06) 0.93	(0.29-	2.96) 1.08	(0.26-	4.58)
14+ 1.54	(0.82-	2.92) 0.25	(0.05-	1.28) 1.19	(0.30-	4.71)
OR, odds ratio.
aAdjusted	for	either	sex	or	age.	
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rSmLy6a.	 The	 sex	 bias	 in	 antibody	 responses	 is	 likely	 due	 to	 the	
males	 in	the	present	study	spending	more	time	in	the	 lake	per	day	
than	females,	 linked	to	their	differing	occupations,	as	has	been	re-
ported previously.44	Although	age	 influences	 immune	responses	to	
Schistosoma adult worm antigens,45,46 the antibody responses against 
recombinant schistosomula antigens used in this study were not age 
dependent.	This	could	imply	that	age	does	not	influence	humoral	re-
sponses	to	the	early	stages	of	schistosome	development.	This	age-	
independent phenomenon may be attributed to the transient nature 
of	 the	post-	penetration	 schistosomula	 in	 the	host	 skin.47	 The	host	
is	 briefly	 exposed	 to	 the	 schistosomula	 in	 a	 natural	 situation,	 and	
therefore,	the	required	antigen	threshold	is	probably	not	reached	to	
build immunity.48,49	This	may	suggest	that	cumulative	exposure	that	
is closely related to age of the host may have no impact on immune 
responses	to	schistosomula	antigens.	The	implication	this	has	on	vac-
cine design is that vaccines based on schistosomula antigens could 
provide	prolonged	exposure	to	a	sufficient	amount	of	schistosomula	
antigen and generate the same level of protection irrespective of age 
of	the	host.	On	the	other	hand,	the	present	study	observed	that	sex	
and age were associated with specific antibody responses to schisto-
some	crude	antigens	AWA	and	SEA	consistent	with	previous	data.45 
Where	participants	had	both	antibody	and	cytokine	data	described	
in	the	companion	paper	(n	=	54),	very	few	weak	correlations	between	
the	antibody	and	cytokine	responses	were	significant.
Antibody	 responses	 to	 Schistosoma antigens are affected by 
treatment	with	 PZQ.20,50	 Praziquantel	 (PZQ)	 is	 the	most	 effective	
drug for treatment of schistosomiasis 51 and is thought to disrupt the 
regulation	of	calcium	(Ca2+)	ion	permeability	through	surface	mem-
branes.52	 The	 resulting	 Ca2+-	induced	 contractions	 are	 sustained,	
which simultaneously paralyse the parasite and dislodge them from 
venules.	 PZQ	 also	 damages	 the	 worm’s	 body	 surface	 by	 forming	
fragile blebs and vacuoles in the schistosome tegument.53	The	blebs	
and vacuoles rupture, damaging the surface and facilitating host 
immune responses against schistosomes.54,55 In addition, treatment 
exposes	 sequestered	 antigens	 and	 antibody	 responses	 towards	
these	 exposed	 antigens	 are	 elevated.54,55	 Although	 the	 effect	 of	
PZQ	on	the	schistosomula	is	thought	to	be	limited,56 treating schis-
tosomula	in	vitro	with	drugs	(PZQ	and	oxamniquine)	exposes	a	mag-
nitude	of	sequestered	antigens	that	are	otherwise	not	accessible	on	
living intact schistosomula.15	However,	not	all	Schistosoma antigens 
induce	an	 increase	 in	antibodies	 following	PZQ	treatment.	For	ex-
ample,	IgG1	levels	against	rSmLy6A	and	rSmLy6B	have	been	shown	
to	 drop	 following	 PZQ	 treatment	 among	 antibody	 responders.16 
Similarly,	we	 also	 found	 a	 drop	 in	 IgG1,	 IgG4	 and	 IgE	 to	 rSmKK7,	
rSmLy6B	and	rSmTSP7,	respectively,	after	PZQ	treatment	among	an-
tibody responders. On the other hand, we did observe an increase 
to	SmLy6A.	These	data	are	in	apparent	contradiction	to	a	previously	
F IGURE  2 The	correlation	between	the	pre-	treatment	and	one	
year	post-	treatment	infection	intensity	of	the	study	participants	
(n	=	240)
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F IGURE  3 The	effect	of	treatment	on	antibody	responses	
against	the	recombinant	schistosomula	antigens	SmKK7	(IgG1:	
n	=	135,	IgG4:	n	=	20	and	IgE:	n	=	51),	SmLy6A	(IgG1:	n	=	25,	IgG4:	
n	=	3	and	IgE:	n	=	4),	SmLy6B	(IgG1:	n	=	163,	IgG4:	n	=	3	and	IgE:	
n	=	90)	and	SmTSP7	(IgG1:	n	=	90,	IgG4:	n	=	8	and	IgE:	n	=	8)	among	
antibody	responders.	The	boxes	indicate	the	interquartile	range	
with	median	as	the	horizontal	line,	while	the	whiskers	indicate	
minimum	and	maximum	antibody	levels.	The	dots	are	outliers.	Pre-	
Tx,	pre-	treatment	antibody	levels;	Post-	Tx,	5	weeks	post-	treatment	
antibody levels; * P	<	0.0125	(P-	value	adjusted	to	take	into	account	
the	multiple	comparison),	**P < 0.01, ***P < 0.001, ****P < 0.0001
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published	study	showing	that	antibodies	to	SmLy6A	decreased	after	
treatment.16	Similar	 to	the	study	by	Chalmers	et	al,16 the effect of 
treatment	was	examined	in	participants	with	an	antibody	response	
above	the	cut-	off	set	using	nonendemic	European	donors	at	base-
line.	However,	the	study	sites	differed	between	the	two	studies,	and	
it is plausible that participants from different endemic areas within 
a country mount differing antibody responses to the same recom-
binant antigens. Our findings suggest that there is heterogeneity in 
the response to Schistosoma antigens following treatment and that 
some antigens induce an immune response and give rise to increased 
antibodies, while other antigens do not.
As	Schistosoma has more than one life cycle stage in the definitive 
host, some Schistosoma antigens are shared across these stages of 
Schistosoma including the schistosomulum, the adult and the egg.57 
As	a	result,	there	is	potential	for	cross-	reactive	antibody	responses	
to	 the	adult	worm,	 the	egg	and	 the	 schistosomula.	The	 schistoso-
mula	antigens	tested	in	the	present	study	SmKK7,	SmLy6a,	SmLy6b	
and	Smtsp7	are	 also	expressed	by	 the	 adults.14,17,57	 These	 studies	
have	shown	that	there	is	a	low	expression	of	the	mRNA	transcripts	
for these antigens in miracidia, sporocysts and cercariae, increasing 
in schistosomula and adult worms. Most importantly, the egg that 
induces the immunopathology associated with chronic schistosomi-
asis	had	minimal	levels	of	transcripts.	Because	treatment	with	PZQ	
alters immune responses to adult Schistosoma antigens,58 it could 
indirectly modify host immune responses to the schistosomula.59 
This	 implies	 that	 cross-	reactive	antibodies	 against	 larvae	 could	be	
boosted	 by	 killing	 the	 adults	 and	 releasing	 antigens.	 Therefore,	
shared epitopes could be good antigens to study further for vaccines 
that target both the schistosomula and the adults.
In longitudinal studies, antibody responses to specific schis-
tosome antigens have been shown to correlate with resistance to 
reinfection.60,61	Generally,	 the	antibody	responses	associated	with	
human resistance to reinfection are directed against the schisto-
some adult worm and not egg antigens.62	This	 finding	may	not	be	
surprising as the immune responses to crude adult worm and egg 
antigens	 have	 been	 widely	 studied.	 However,	 limited	 work	 has	
shown	that	IgG	32	and	IgE	31 antibody responses to larval antigens 
are	associated	with	resistance	to	reinfection.	By	looking	at	those	in-
fected	individuals	who	were	cured	five	weeks	following	treatment,	
we related their reinfection intensity to antibody responses to schis-
tosomula	 antigens	 pre-	treatment	 and	 five	 weeks	 post-	treatment.	
Determinants	 of	 reinfection	 (reviewed	 in38)	 we	 considered	 in	 this	
analysis	were	age	and	sex.	In	the	present	study,	pre-	treatment	or	five	
weeks	post-	treatment	antibody	responses	against	schistosomula	an-
tigens	were	not	associated	with	one	year	post-	treatment	reinfection	
intensity.	These	findings	imply	that	although	the	schistosomula	anti-
gens	tested	in	the	present	study	were	targeted	by	IgG1	and	IgE,	the	
responses were not protective. With the schistosomula as the target 
of	 immune	 attrition,	 using	 the	 radiation-	attenuated	 cercariae	 the	
only	experimental	vaccine	to	date	to	consistently	provide	high	lev-
els	of	protective	immunity	(60%-	80%)	against	challenge,63-65 there 
is a need to identify other schistosomula antigens that are targets of 
protective immunity in humans. It could be that other, perhaps non-
protein, schistosomula molecules such as glycans may be targets of 
protective	immunity	in	humans.	A	glycomic	analysis	of	the	life	cycle	
of S. mansoni	shows	stage-	specific	expression	of	glycans,	 including	
during the schistosomula stage.66	 Glycans	 are	 highly	 antigenic,67 
and schistosomula glycans are the dominant targets of antibody 
Antibody Antigen Crude OR (95% CI) P- value Adjusteda OR (95% CI) P- value
IgG1 rSmKK7 0.71	(0.34-	1.51) 0.377 1.01	(0.44-	2.30) 0.986
rSmLy6A 0.27	(0.11-	0.64) 0.004 0.43	(0.16-	1.11) 0.082
rSmLy6B 0.50	(0.24-	1.07) 0.073 0.80	(0.35-	1.82) 0.592
rSmTSP7 0.93	(0.43-	1.96) 0.838 1.02	(0.45-	2.31) 0.956
AWA 0.21	(0.01-	3.58) 0.287 0.62	(0.04-	10.47) 0.741
SEA 1.59	(0.18-	13.39) 0.668 2.18	(0.23-	19.97) 0.489
IgG4 rSmKK7 0.49	(0.13-	1.73) 0.269 0.58	(0.15-	2.27) 0.439
rSmLy6A 0.72	(0.19-	2.60) 0.616 0.70	(0.18-	2.76) 0.608
rSmLy6B 0.37	(0.08-	1.65) 0.193 0.42	(0.09-	2.05) 0.285
rSmTSP7 1.56	(0.46-	5.16) 0.470 2.17	(0.56-	8.48) 0.265
AWA 0.89	(0.18-	4.39) 0.885 1.04	(0.19-	5.74) 0.964
SEA -	 -	 -	 -	
IgE rSmKK7 0.74	(0.29-	1.94) 0.546 0.82	(0.29-	2.29) 0.701
rSmLy6A 0.72	(0.19-	2.59) 0.616 0.54	(0.14-	2.09) 0.371
rSmLy6B 0.98	(0.45-	2.10) 0.950 1.34	(0.57-	3.12) 0.496
rSmTSP7 0.68	(0.18-	2.43) 0.551 0.48	(0.12-	1.82) 0.279
AWA 1.29	(0.59-	2.84) 0.527 1.10	(0.46-	2.62) 0.825
SEA 1.31	(0.63-	2.78) 0.468 1.19	(0.53-	2.71) 0.671
OR, odds ratio.
aAdjusted	for	sex	and	gender.	
TABLE  5 Association	between	
detectable	five	weeks	post-	treatment	
IgG1,	IgG4	and	IgE	responses	against	
schistosomula antigens and reinfection 
intensity
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responses.68-70	There	 is	 evidence	 that	 schistosome	glycans	 induce	
protective	immune	responses.	For	instance,	anti-	glycan	IgG	protects	
mice against challenge with S. japonicum.71	 Furthermore,	 glycan-	
specific	IgG	antibodies	have	been	associated	with	the	ability	of	non-
human primates to naturally clear Schistosoma infections.72 In the 
present study, the recombinant schistosomula proteins were gener-
ated in an E. coli system without the ability to glycosylate proteins. 
Therefore,	 the	 antibody	 responses	 to	 schistosomula	 glycoproteins	
could	not	be	established.	As	it	is	now	possible	to	use	an	engineered	
E. coli system to produce recombinant glycoproteins,73,74 schistoso-
mula	glycans	 (in	the	form	of	recombinant	glycoproteins)	should	be	
investigated	 further	 for	a	possible	 role	 in	human	anti-	schistosome	
immunity	and	subsequently	their	potential	as	vaccine	candidates.75
In addition to identifying the antibodies that target schistoso-
mula antigens, another important issue to consider during the devel-
opment of a schistosomiasis vaccine is whether the schistosomula 
antigens	induce	IgE.	IgE	responses	to	worm	antigens	correlate	with	
age-	dependent	 human	 immunity,20,76-78	 but	 IgE	 has	 also	 been	 ob-
served to mediate allergic reactions to helminth antigens in pre-
viously infected people.23 In the present study, the relatively high 
IgE	 responses	 to	 rSmKK7	and	 rSmLy6B	would	 indicate	 that	 these	
antigens could be potentially allergenic if developed further as vac-
cine candidates and thus are probably not a good avenue for further 
development.	This	finding	could	point	to	a	new	class	of	possible	IgE-	
binding protein families that have never been seen before. Whether 
the	 IgE	 levels	 to	 the	 schistosomula	 antigens	 are	 sufficient	 to	 lead	
to	 allergic	 responses/cross-	reactivity	 remains	 to	 be	 investigated.	
Possible	vaccine-	induced	allergic	 reactions	can	be	mitigated	when	
selecting vaccine antigens by in silico screening out of potentially 
allergenic	antigens	using	bioinformatics	tools,	such	as	the	Structural	
Database	of	Allergenic	Proteins	 (SDAP),	 that	predict	 antigens	 that	
IgE	binds.79	This	was,	in	fact,	performed	for	the	schistosomula	anti-
gens	used	 in	this	study,	by	TheSchistoVac	(http://www.theschisto-
vac.eu/).	Our	present	study	cohort	(the	Namoni	cohort)	is	a	similar	
cohort	to	the	Musoli	cohort	(also	in	Uganda)	but	showed	that	there	
were	individuals	with	high	IgE	responses	to	some	of	the	schistoso-
mula	antigens.	There	appears	 to	be	heterogeneity	 in	 the	response	
to schistosomula, even between geographically close populations 
(Musoli	vs	Namoni).	It	may	be	that	across	a	population,	there	will	be	
people that respond to any novel Schistosoma	antigen	with	IgE,	and	it	
may not be possible to screen this reactivity out, meaning that there 
may be some people who will end up with an adverse reaction to 
any	novel	antigen.	Of	course,	if	the	risk	is	small	and	can	be	managed,	
then the benefit of administering an antischistosome vaccine will far 
outweigh	the	risks.
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